509 reports of this reaction
2.0% of all BIMEKIZUMAB reports
#12 most reported adverse reaction
ORAL CANDIDIASIS is the #12 most commonly reported adverse reaction for BIMEKIZUMAB, manufactured by UCB, Inc.. There are 509 FDA adverse event reports linking BIMEKIZUMAB to ORAL CANDIDIASIS. This represents approximately 2.0% of all 25,281 adverse event reports for this drug.
BIMEKIZUMAB has an overall safety score of 65 out of 100. Patients taking BIMEKIZUMAB who experience oral candidiasis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ORAL CANDIDIASIS is a less commonly reported adverse event for BIMEKIZUMAB, but still significant enough to appear in the safety profile.
In addition to oral candidiasis, the following adverse reactions have been reported for BIMEKIZUMAB:
The following drugs have also been linked to oral candidiasis in FDA adverse event reports:
ORAL CANDIDIASIS has been reported as an adverse event in 509 FDA reports for BIMEKIZUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
ORAL CANDIDIASIS accounts for approximately 2.0% of all adverse event reports for BIMEKIZUMAB, making it a notable side effect.
If you experience oral candidiasis while taking BIMEKIZUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.